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Abstract
Although the human and societal burden and cost of COPD is staggering, there are few clinical tools that provide
earlier diagnoses or a means to regionally monitor disease in a way that might lead to improved therapies and
outcomes. In acknowledgement of the current gaps in COPD therapy, the objective of the Thoracic Imaging
Network of Canada (TINCan) is to improve COPD patient phenotyping through imaging, to provide methods and
imaging-based intermediate endpoints for the development of new treatments, and to evaluate disease progression
and patient-based outcomes in COPD patients and those at risk of COPD. Here we summarize and outline the
TINCan study protocol and describe our objectives. TINCan is a prospective study that aims to identify and
quantify novel COPD phenotypes from thoracic computed tomography (CT) and thoracic hyperpolarized noble
gas magnetic resonance imaging (MRI) in 200 ex-smokers, 50 years of age or greater, including asymptomatic
ex-smokers with normal pulmonary function and Global initiative for chronic Obstructive Lung Disease (GOLD)
Unclassified (U) , and GOLD stages I-IV patients. Baseline and 2-year follow-up measurements will be acquired
using spirometry, plethysmography, diffusing capacity of the lung for carbon monoxide (DLCO), St. George’s
Respiratory Questionnaire (SGRQ), 6-minute walk test (6MWT), thoracic CT and hyperpolarized helium-3
(3He) and xenon 129 (129Xe) MRI. TINCan provides a unique opportunity to quantify and compare novel lung
structure-function measurements and investigate their relationship with well-established clinical measurements
and outcomes. Such intermediate endpoints of COPD may be used to stratify patients for personalized treatments
and to develop new treatments to improve outcomes, a long-standing clinical goal.
Abbreviations: Thoracic Imaging Network of Canada, TINCan; computed tomography, CT; magnetic resonance imaging, MRI; Global
initiative for chronic Obstructive Disease, GOLD; diffusing capacity of the lung for carbon monoxide, DLCO; St. George’s Respiratory
Questionaire, SGRQ; 6-minute walk test, 6MWT; helium-3, 3He; xenon-129, 129Xe; COPD Genetic Epidemiology, COPDGene; Global
Chest Symptoms Questionaire, GCSQ; Capacity of Daily Living questionnaire, CDLM; Food Frequency Questionaire, FFQ; Community
Healthy Activities Model Program for Seniors, CHAMPS; Short Form-36 version 2, SF-36V2; Hospital Anxiety and Depression Scale,
HADS; Short Form of the Health and Labour Questionaire, SF-HLQ; COPD Assessment Test, CAT; cardiopulmonary exercise test, CPET;
Centre for Epidemiological Studies of Depression, CES-D; Functional Assessment of Chronic Illness Therapy, FACIT; Canadian Chronic
Obstructive Lung Disease study, CanCOLD; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints, ECLIPSE;
Subpopulations and Intermediate Outcomes Measures in COPD, SPIROMICS; American Thoracic Society, ATS; European Respiratory
Society, ERS; forced expiratory volume in 1 second, FEV1; functional residual capacity, FRC; residual volume, RV; total lung capacity, TLC;
percent of predicted value, %pred; nitrogen gas, N2; lumen area, LA; airway wall area, Aaw; wall area percentages, WA%; internal perimeter
of 10mm, Pi10; Hounsfield units, HU; relative area with attenuation values below -950, RA-950; low attenuation cluster, LAC; ventilation
defect volume, VDV; ventilation defect percent, VDP; apparent diffusion coefficient, ADC; zero-inflated Poisson, ZIP
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Introduction
Chronic obstructive pulmonary disease (COPD) affects
over 600 million people1 and is the third leading cause
of death worldwide.2 Despite the huge societal, patient
and health care system burden,3,4 COPD remains largely
underdiagnosed5,6 and undertreated.7 Although COPD
is currently diagnosed and its severity graded by nonfully-reversible airflow limitation, there is tremendous
heterogeneity in the underlying regional abnormalities
within and across COPD severity categories.8 However,
until recently, COPD patient measurements have been
dominated by airflow and physiological measurements
(e.g. inert gas washout tests9), or invasive histological
measurements and this has limited the scope of research
related to regional COPD phenotypes and their effect
on outcomes and disease pathogenesis.
Unlike spirometry and other measurements made at
the mouth, pulmonary imaging provides quantitative,
regional and independent measurements of the
underlying disease contributions in COPD.10,11 It is
well-established that x-ray computed tomography (CT)
provides a way to non-invasively measure the extent
and regional distribution of emphysema and airway
wall thickening in COPD10,12-14 CT measurements
also correlate significantly with mortality,15
disease progression,16-18 and exacerbation risk19
and may identify suitable candidates for surgical
intervention.20-23 Complementary to this, pulmonary
functional imaging using hyperpolarized noble gas
(3He and 129Xe) magnetic resonance imaging (MRI)24
provides unique and simultaneous microstructure
and functional information of both the airways
and parenchyma. MRI pulmonary structural and
functional abnormalities are spatially reproducible over

time25-29 and correlate moderately with pulmonary
function measurements.11,30-34
Unfortunately, unlike the case for many chronic
diseases where in vivo imaging has been exploited to
improve patient outcomes, the inclusion of imaging in the
clinical workup and prospective study of COPD therapies
remains very limited.35, 36 Recently, however, large,
prospective, multi-center cohort studies of COPD, such
as the COPD Genetic Epidemiology (COPDGene)37
the Canadian Chronic Obstructive Lung Disease
(CanCOLD),38 the Evaluation of COPD Longitudinally
to Identify Predictive Surrogate Endpoints (ECLIPSE)39
and the Subpopulations and Intermediate Outcomes
Measures in COPD (SPIROMICS)40 studies as shown in
Table 1, have included CT endpoints. Although these
multi-center studies have provided a wealth of clinical
and biological data, there are no longitudinal COPD
studies that have incorporated emerging and nonradiation based imaging methods, such as provided by
1
H and hyperpolarized noble gas MRI. Emerging MRI
approaches may provide complementary functional
and microstructural information related to COPD
disease heterogeneity and progression. Hence, the
overarching objective of the Thoracic Imaging Network
of Canada (TINCan) study is to determine quantitative
structural and functional COPD imaging phenotypes
that can be used to improve health outcomes in
COPD patients. The 4 key objectives of TINCan are:
1) determine the significant cross-sectional univariate
and multivariate relationships for 3He with 129Xe MRI
and CT-derived phenotypes of airway and parenchymal
abnormalities, 2) determine the longitudinal changes
and relationships for 3He MRI-derived phenotypes
of airway and parenchymal abnormalities with other
COPD measurements, 3) determine the associations
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between MRI and CT imaging phenotypes of COPD
with exacerbations, and 4) determine whether MRI and
CT phenotypes are predictors of longitudinal changes
in pulmonary function measurements, lung volumes,
symptoms and functional capacity. To our knowledge,
this is the first such large patient group comparison
of structure-function imaging with prospective crosssectional and longitudinal components. This study was
designed to be complementary to larger ongoing COPD
investigations and to address some of the important
information gaps that remain. Here we describe the
study plan and aims for TINCan and the potential
impact of this study to improve our understanding of
COPD patient phenotypes.

Methods
Participants
As shown in the schedule of study assessments in Table
2, plans are to enroll 200 participants who will attend
a baseline and a two-year follow-up visit. Imaging
evaluations include thoracic CT and hyperpolarized
3
He MRI at baseline and follow-up imaging at year two
using both 3He and 129Xe MRI as well as CT. Imaging

will be performed at Robarts Research Institute
(Ontario, Canada); MR image analysis will be performed
at Robarts Research Institute and CT image analysis
will be performed at Vancouver General Hospital
(Vancouver, Canada). The goal is to recruit 200 exsmokers with and without COPD between 50 and 80
years of age, including approximately 100 ex-smokers
without airflow limitation and COPD Global initiative
for chronic Obstructive Lung Disease (GOLD) stage
Unclassified (U) and 100 ex-smokers with COPD GOLD
stages I, II, III and IV. We previously demonstrated
significant longitudinal changes in COPD ex-smokers
in a two-year longitudinal pilot study and therefore, we
limited our evaluation to ex-smokers. Ex-smokers had
ceased smoking ≥1-year prior to the study visit but
there was no maximum cut-off for when ex-smokers
had ceased smoking. COPD was defined as postbronchodilator forced expiratory volume in 1 second
(FEV1)/forced vital capacity (FVC) ratio less than 0.70
according to the modified GOLD criteria.1
Recruitment and Retention
As shown in Figure 1, thus far, 231 potential participants
have
been
screened
for participation in the
TINCan study; of those 231
individuals, 23 individuals
cancelled prior to consent, 6
individuals refused consent,
16 individuals were excluded
due to MRI incompatibilities
and 4 individuals were
excluded because they were
unable to perform the 3He
gas inhalation and breathhold. Thus far, a total of
182
participants
have
completed visit 1 and their
demographic and pulmonary
function measurements are
provided in Table 3. The
projected recruitment phase
for TINCan is 2 years. An
important goal of TINCan
is to provide a better
understanding of the early or
mild subclinical disease, and
therefore we plan to enroll a
large number of ex-smokers
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with normal pulmonary function. Thus far, a total of 75
ex-smokers without airflow limitation or GOLD U and
107 individuals with COPD, including GOLD stage I
(n=22), GOLD stage II (n=49), GOLD stage III (n=29)
and GOLD stage IV (n=7), have been enrolled.
Participant recruitment was primarily performed
by local academic pulmonologists, advertisement in
local newspapers, community newsletters and a local
atherosclerosis prevention clinic. All participants
will provide written informed consent to the protocol
that was approved by a local research ethics board
and Health Canada and compliant with the Health
Insurance Portability and Accountability Act. Review
and documented consent will be performed during
the follow-up visit prior to participant evaluations.
The primary responsibility of a full-time research
coordinator (certified by the Association of Clinical
Research Professionals) included management of
recruitment and scheduling as well as participant
retention activities. Based on our previous experience
with a pilot two-year longitudinal study where the
retention rate was 90%,41 we expect similar participant
retention over the two-year follow-up period.
For TINCan, 231 individuals were contacted and 208 individuals
attended the baseline study visit. Of the 208 individuals who
attended the baseline visit, 6 individuals refused consent, 16
individuals were excluded due to MRI incompatibilities and 4
individuals were excluded because they were unable to perform the
3
He gas inhalation and breath-hold. Complete visits, defined as one
in which individuals were able to complete all study evaluations
was performed for 182 individuals; 75 individuals did not have
airflow limitation (FEV1/FVC≥0.70) and 107 individuals had
COPD defined using spirometry according to GOLD criteria.1

Pulmonary Function and Other Measurements
All participants will undergo, at baseline and at the
two-year follow-up, post-bronchodilator spirometry
and plethysmography, the St George’s Respiratory
Questionnaire (SGRQ), used with permission,42
and a 6-minute walk test (6MWT)43,44 to measure
the 6-minute walk distance (6MWD). Spirometry,
plethysmography and diffusing capacity of the lung for
carbon monoxide (DLCO) will be measured
using body plethysmography (MedGraphics
Corporation, Minnesota, USA) with the
attached Medgraphics gas analyzer
according to American Thoracic Society
(ATS)/European
Respiratory
Society
(ERS) guidelines.45-48 For all participants
who complete the baseline study visit,
the number of acute exacerbations
requiring hospitalization or COPD-related
hospitalizations will be reported using
patient hospital records obtained with
Cerner’s PowerChart® (Cerner Corporation,
Missouri, USA) up to 5 years prior to the
initial participant baseline visit as well as
during the follow-up period.
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CT Imaging
Thoracic CT will be acquired using a 64-slice (General
Electric Health Care Milwaukee) CT system. Baseline
CT images will be acquired with patients at inspiration
breath-hold after inhalation of 1.0L medical grade
nitrogen (N2) from a 1.0 L Tedlar® bag (Jensen Inert
Products, New Jersey, USA) from functional residual
capacity (FRC) using the same imaging protocol as the
ECLIPSE study39 and the same lung volume used with
an MRI. We use a Tedlar® bag filled with N2 instead of
room air for CT imaging because the hyperpolarized
3
He gas depolarizes when exposed to oxygen (O2) and
therefore, the gas dispensing apparatus must remain
completely free of O2 in order to avoid the potential for
cross-contamination. The baseline CT is acquired at the
same lung volume as used with an MRI to enable image
co-registration; CT-MRI co-registration will allow us
to investigate the relationship between morphological
CT airway measurements and hyperpolarized noble
gas MRI static ventilation measurements. In order
to evaluate regional pulmonary gas trapping, as
well as to differentiate regions of gas trapping due
to emphysematous tissue destruction from small
airway disease using inspiratory to expiratory image
registration,49 a full inspiration and full expiration
CT will be performed at the two-year follow-up using
the same imaging protocol as the COPDGene37 and
CanCOLD38 studies. Importantly, the CT images
acquired at the two-year longitudinal follow-up will
not be used to evaluate longitudinal measurement
changes. Both baseline and longitudinal CT will be
used for investigating relationships between MRI and
CT measurements.
All CT images will be quantified using the Pulmonary
Workstation 2.0 (VIDA Diagnostics, Inc., Iowa, USA).
CT structural airway measurements will include: 1)
lumen area (LA), 2) airway wall area (AAW) and 3) wall
area percentage (WA%) measured for the segmental and
subsegmental airways,10 and, 4) the square root of airway
wall thickness for airways with an internal perimeter of
10mm (Pi10).50 CT structural emphysema measurements
will include: 1) the relative area with attenuation values
below −950 Hounsfield units [HU] (RA950),13 and, 2)
the low attenuation cluster (LAC) analysis of connected
regions with CT densitometry values < -950 HU.51-53
At the two-year follow-up, inspiratory and expiratory
CT images will be co-registered to regionally identify
normal lung, emphysema and air trapping as recently
described.49

MR Imaging
Hyperpolarized 3He MRI will be acquired using a 3.0
Tesla MR750 system (General Electric Health Care,
Milwaukee, WI USA). Participants will undergo breathhold imaging for acquisition of conventional 1H MRI,
3
He static ventilation MRI and 3He diffusion-weighted
MRI. Conventional 1H MRI will be acquired during 1.0L
breath-hold of N2 from a 1.0 L Tedlar® bag from FRC.
3
He static ventilation and diffusion weighted imaging
will be performed following inhalation of a 3He/N2 gas
mixture (3He dose = 5 ml/kg body weight) from a 1.0
L Tedlar® bag from FRC as previously described.25 At
visit 2, a hyperpolarized 129Xe MRI will also be acquired
on the same system as 3He MRI using 129Xe gas doses
(50/50 129Xe/4He) administered in 1.0L Tedlar®
bags with 129Xe MRI static ventilation and diffusionweighted images acquired, as previously described.34
There was not a commercially-available 129Xe polarizer
that was approved for human participants during
baseline enrollment, and therefore, hyperpolarized
129
Xe was not performed at visit 1 for all participants.
However, a small proof of concept study was performed
in 10 TINCan COPD participants at visit 1 as previously
described.34
All MR images will be evaluated using custom-built
software generated using MATLAB R2007b (The Mathworks Inc., Massachusetts, USA). For 3He and 129Xe
MRI static ventilation images, regions of signal void or
ventilation defects will be quantified as the ratio of the
ventilation defect volume (VDV) to the thoracic cavity
volume (segmented from 1H MRI) to generate the whole
lung ventilation defect percentage (VDP)11,54; 3He
and 129Xe apparent diffusion coefficient (ADC) maps
will also be generated from diffusion-weighted images
using custom built software (MATLAB R2007b) .55
Figure 2 shows for 2 representative asymptomatic
ex-smokers with normal pulmonary function and 2
representative COPD participants at baseline, the CT
density mask highlighting areas with CT densitometry
values less than -950 HU, CT low attenuation clusters
registered to the 3D reconstruction of the CT airway tree
for measurement of airway dimensions. The 1H and 3He
MRI co-registered central coronal slices (3He shown in
blue) are also shown to highlight 3He MRI ventilation
defects, and the 3He MRI ADC maps are provided
as evidence of both ventilation and morphological
abnormalities in these individuals.

For personal use only. Permission required for all other uses.

journal.copdfoundation.org JCOPDF © 2014

Volume 1 • Number 2 • 2014

206

TINCan: Imaging Phenotypes of COPD

and 129Xe gas distribution measurements
(regional and whole lung VDV, VDP) with CT
airway disease measurements and all other
participant measurements.
Multivariate
linear regression models will also be
constructed for predicting SGRQ total score
and 6MWD using CT (Pi10, RA950) and 3He
MRI (VDP, ADC) phenotype measurements,
adjusted for sex, BMI, FEV1, and DLCO.
Second, we will determine the longitudinal
changes and relationships for 3He
MRI-derived phenotypes of airway and
parenchymal abnormalities with other
COPD measurements (SGRQ, 6MWD,
spirometry, plethysmography and DLCO). We
will determine the significant longitudinal
changes for 3He MRI measurements
using paired two-tailed t-tests. Pearson
correlation coefficients and linear regression
analyses will be performed to determine the
relationships between the change in 3He MRI
measurements with the longitudinal change
in physiological measures (FEV1, FEV1/
FVC, RV, DLCO), functional capacity (6MWD)
and quality of life (SGRQ) measurements.
We previously performed and reported the
results of a pilot longitudinal study in 15
For 4 representative participants (2 asymptomatic ex-smokers without COPD and 2 COPD
ex-smokers with COPD that demonstrated
ex-smokers) the CT density mask highlighting areas with CT densitometry values below
3
-950 HU, CT LAC of connected regions of the lung with CT densitometry values below statistically significant41 He ADC and VDP
Based on this pilot
-950 HU registered to the 3D reconstruction of the airway tree for measurement of airway worsening in 2 years.
dimensions, 1H and 3He MRI registration (3He shown in blue) and 3He ADC maps are shown. study, with 100 COPD participants enrolled
Imaging evidence of disease is apparent in some asymptomatic ex-smokers without COPD, thus far and a longitudinal retention rate of
as shown for Participant 2 (72 year-old male, FEV1=122%pred, FEV1/FVC=80%, DLCO=73%pred, 90% expected, this study has sufficient power
RA950=4%, VDP=17%, ADC=0.25cm2/s) but not Participant 1 (70 year-old male, to detect significant longitudinal changes for
FEV1=101%pred, FEV1/FVC=75%, DLCO=113%pred, RA950=1%, VDP=4%, ADC=0.26cm2/s). 3He MRI measurements (α=.05, ß=0.20 and
For the COPD ex-smokers, significantly greater emphysema extent is demonstrated by power=.80).
the highlighted areas on the CT density mask and bright ADC maps in Participant 4 (76
Third, the associations between imaging
year-old female, FEV1=79%pred, FEV1/FVC=64%, DLCO=63%pred, RA950=33%, VDP=36%, phenotypes of COPD with exacerbations
ADC=0.63cm2/s), while a lesser extent is observed for Participant 3 (76 year-old female,
will be evaluated. To accomplish this, a zeroFEV1=52%pred, FEV1/FVC=42%, DLCO=18%pred, RA950=1%, VDP=17%, ADC=0.31cm2/s).
inflated Poisson (ZIP) model will be used to
Data and Statistical Analysis Plan
determine the relationship between selected variables
There are 4 key objectives for the TINCan study and
with COPD exacerbations, including hospitalization
these are enabled by the statistical analysis plan.
and death. The variables that will be included in the
First, we will determine the significant cross-sectional
regression include: age, sex, BMI, smoking status, FEV1,
univariate and multivariate relationships for 3He with
DLCO, RV, SGRQ, 6MWD, CT RA950, CT WA%, 3He MRI
129
Xe MRI and CT-derived phenotypes of airway
VDP, and 3He MRI ADC. We have recently evaluated the
and parenchymal abnormalities. Pearson correlation
association between imaging phenotypes of COPD with
coefficients and linear regression will be performed to
the number of hospitalizations and demonstrated that
determine the univariate relationships for baseline 3He
over a 5-year period, 58 hospitalizations occurred.56 We
For personal use only. Permission required for all other uses.
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also reported that 3He VDP was a significant predictor
of hospitalization due to COPD exacerbation.56
Therefore, based on this study we are powered to detect
statistically significant associations between 3He MRI
measurements with all COPD acute exacerbations,
including those that resulted in treatment, emergency
department visits and hospitalizations, as well as
COPD-related mortality.
Finally, we will determine whether MRI and CT
phenotypes are predictors of longitudinal changes
in pulmonary function measurements, lung volumes,
symptoms and functional capacity. Using mixed
linear regression analyses adjusted for cofounders,
we will determine which baseline imaging phenotype
measurements have the strongest relationship with
the longitudinal changes in health status (SGRQ),
functional capacity (6MWD) and FEV1. Cofounders
will include age, sex, smoking status, BMI, and baseline
FEV1. In a similar manner we will also use hierarchical
clustering models (Principal Component analysis)
and generate icicle plots (showing cases as rows and
number of clusters as columns) and dendograms (or
hierarchical tree diagrams). Principal component
analysis using hierarchical clustering is appropriate
for smaller samples (typically < 250) and we will
generate a dataset for all evaluable participants with
3
He and 129Xe MRI structural and functional variables
as well as CT-derived variables. In this way, we can
attempt to determine which clusters of imaging and
other measurements are the predictors of longitudinal
progression and outcomes.

Discussion
In COPD, the current gold standard approach for
evaluating disease severity, disease progression
and treatment response relies on lung function
measurements that provide little information about the
underlying morphological, anatomical and functional
abnormalities that result in symptoms, airflow limitation
and adverse outcomes. To address this critical gap in
knowledge, TINCan was developed and implemented.
The major anticipated value of TINCan is an enhanced
understanding of COPD-imaging phenotypes, and
their relationship to well-established measurements of
COPD and subclinical disease and disease progression.
In addition, we hypothesize that non-invasive COPDimaging phenotypes directly reflect the underlying

abnormalities in COPD and these can be used as
intermediate endpoints in the development of new
treatment approaches.
One important technical goal for TINCan is to provide
tools and methods that streamline image analysis
workflow to accelerate the translational potential of
pulmonary functional MRIs. Therefore, we focused
on developing image segmentation and registration
tools to quantify measurements with high precision for
detecting small measurement changes in treatment or
longitudinal studies. Towards this goal, we developed
a multi-step, semi-automated 3He-1H registration
and segmentation method57 and demonstrated that
it provides excellent inter-/intra-observer precision
and good agreement with expert observers’ manual
measurements.
With the development of image
analysis tools underway, we can apply these tools to the
TINCan cohort and be confident that the longitudinal
changes measured are likely due to disease changes.
Another important goal of TINCan is to provide a better
understanding of the early or mild subclinical disease
observed in ex-smokers with normal spirometry. We
recently demonstrated that abnormal DLCO in exsmokers without COPD was related to worse health
status, functional capacity and elevated 3He ADC
consistent with early emphysema revealed by 3He MRI
but not CT.58 At the 2-year follow-up, we will determine
whether such smokers with 3He MRI evidence of early
or mild emphysema (but without airflow limitation)
show evidence of progressive disease.
For a small group of participants we have incorporated
hyperpolarized 129Xe MRI as part of the baseline visit
to test hypotheses related to potential differences in
129
Xe and 3He MRI ventilation. To better understand
any potential differences between 3He and 129Xe MRI
gas distribution, we quantitatively compared 3He and
129
Xe MRI in COPD participants and observed that
129
Xe VDP was significantly greater than 3He VDP.34
We also observed that the regions of decreased 129Xe
ventilation were spatially and significantly correlated
with regions of emphysema.33 Taken together, these
important findings suggest that 129Xe gas may be more
sensitive to changes in both the airways and parenchyma
in COPD, and therefore may be more sensitive than 3He
for detecting changes at the 2-year follow-up.
The important next step of the TINCan cohort
is to complete enrollment and then follow-up with
all participants in order to evaluate longitudinal
changes. We will identify whether MRI phenotypes
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detect significant disease progression, how changes
in MR imaging-derived measures relate to changes in
physiologic and health outcome measurements, and
determine which baseline imaging phenotypes can
predict declines in quality of life, functional capacity
and physiologic measurements. We will also determine
whether imaging phenotypes can independently
identify individuals with more frequent exacerbations
and more rapid declines in lung function.
In contrast to other cohort studies of COPD,37-40
TINCan’s novelty stems from its incorporation of
emerging non-radiation-based imaging measurements
in addition to conventional CT. These emerging imaging
methods have the potential to provide complementary
quantitative information regarding subclinical and
clinical COPD pathophysiologies that may eventually
allow for more personalized treatment.
Another
strength of TINCan is the inclusion of individuals often
excluded from COPD cohort studies. For example,
TINCan includes a relatively large group of ex-smokers
without COPD.
Identifying imaging phenotypes
that can characterize these unique pathologies noninvasively and evaluate their relationships with disease
progression and exacerbations is an important goal for
the TINCan study.
In conclusion, here we describe the largest prospective,
longitudinal pulmonary structure-function imaging
study of COPD planned to-date using emerging
MRI and CT imaging methods. Upon completion we
will have a better understanding of the relationships
between imaging phenotypes with well-established
lung function and health status measurements, as well

as outcomes, in a well-defined and relatively large group
of ex-smokers. Finally, once complete, the resulting
validated imaging measurements may be considered
as intermediate endpoints for future COPD treatment
studies to better target therapy, a long-standing research
and clinical goal for COPD.
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